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RAPPORT DE SYNTHESE 
L'inactivation de gènes par une hyperméthylation de leur promoteur apparaît être un événement 
épigénétique fréquent, se retrouvant dans de nombreuses tumeurs. Dans cette étude, nous avons 
investigué dans des mélanomes primaires de l'uvée l'état de méthylation du promoteur de gènes 
fréquemment impliqués dans le développent tumoral tels que pl 6, TIMP3, RASSFI, RARE, 
FHIT, hTERT et APC. La méthylation des promoteurs de gènes a été étudiée par methylation-
sensitive single-strand conformation analysis (MS-SSCA) et dot blot assay (MS-DBA) dans une 
série de 23 mélanomes primaires de l'uvée. Tous les échantillons tissulaires provenaient de 
matériel fixé dans le formol et conservé dans des blocs de parraffine. Nous avons identifié une 
fréquence relativement élevée (52%) pour la méthylation du promoteur de hTERT. En ce qui 
concerne le reste des gènes étudiés, nous avons retrouvé des fréquences de méthylation de 
promoteurs relativement basses avec 13 % pour RASSF 1, 13 % pour RARE 13 %, 9% pour TIMP 3 
et 4% pour pl 6. Nous n'avons pas retrouvé d'hyperméthylation des promoteurs des gènes APC 
etFHIT. 
La méthylation de hTERT apparaît être un événement important dans la biologie du mélanome 
de l'uvée. L'hyperméthylation des autres gènes évalués ne semble pas être cruciale dans le 
développent de cette tumeur. Comme la méthylation des promoteurs des gènes APC, RASSFI et 
RARE a été fréquemment observée dans le mélanome de la peau, notre étude tend à démontrer 
que des mécanismes épigénétiques différents surviennent dans le développement respectif de ces 
tumeurs. 
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Methylation of CpG island promoters m uveal 
melanoma 
A P Moulin,1'2 G Clément, 1 F T Bosman, 1 L Zografos, 2 J Benhattar1 
ABSTRACT 
Background: Inactivation of tumour-related genes by 
promoter hypermethylation is a common epigenetic event 
in the development of a variety of tumours. 
Aim: T o investigate in primary uveal melanoma the status 
of promoter methylation of genes thought to be involved 
in tumour development: p16, TIMP3, RASSF1, RARB, 
FHIT, hTERT and APC. 
Methods: Gene promoter methylation was studied by 
methylation-sensitive single-strand conformation analysis 
and dot-blot assay in a series of 23 primary uveal 
melanomas. Ali DNA samples were obtained from 
paraffin-embedded formalin-fixed tissue blacks. 
Results: h TERT promoter methylation was found with a 
relatively high frequency (52%). Promoter methylation of 
p16, TIMP3, RASSF1, RARB, FHIT and APC was a rare 
event. For none of these genes did promoter methylation 
exceed 15% of tumour samples, and, for some genes 
(FHIT and APC), no methylation was found at ail. 
Furthermore, promoter methylation was absent in 39% (9/ 
23) of cases. ln only 22% (5/23) of cases was 
hypermethylation of at least two promoters observed. 
Conclusions: Promoter methylation of h TERT is a regular 
event in uveal melanoma. Hypermethylation of the other 
genes studied does not seem to be an essential element 
in the development of this tumour. As promoter 
methylation of APC, RASSF1 and RARB is often observed 
in cutaneous melanoma, these results suggest that 
different epigenetic events occur in the development of 
cutaneous and uveal melanoma. 
Uveal melanoma is the most common primary 
intraocular tumour in adults, with a stable incidence 
of 4.3 new cases per million per year over the last 25 
years. 1 Despite new treatment modalities, mortality 
has not decreased,2 mainly because of liver metas-
tases. Although numerous studies have addressed the 
genetic events involved in the development of uveal 
melanoma, only a few have focused on the epigenetic 
events that may occur during tumorigenesis. 
CpG islands promoter methylation, associated 
with transcriptional gene silencing, has emerged as 
one of the most important epigenetic alterations in 
the development of human malignancies.3 Promoter 
methylation has been observed in many tumour 
types,4 5 but there are few reports on uveal mela-
noma. p16 promoter has been found to be methy-
lated in up to 32% of primary tumours and 50% of 
cell lines. 6-s In derived cell lin es, TIMP3 expression 
was found to be lower in liver metastatic cells than 
primary uveal tumour, and it was suggested that 
TIMP3 promoter methylation may be the cause of 
TIMP3 downregulation.9 More recently, RASSF1 
promoter methylation was identified in 50% of 
primary uveal melanoma, and a correlation was 
noticed between RASSF1 promoter methylation 
status and the development of metastasis. 10 
Although cutaneous and uveal melanoma share 
common morphological features, they differ sub-
stantially in their behaviour, metastatic spread and 
response to chemotherapy. There is increasing 
evidence that this is related to differences in their 
molecular phenotype. cDNA analysis has revealed 
that uvea[ and cutaneous melanoma cell lines have 
different expression profiles. 11 BRAF mutations, 
often observed in cutaneous melanoma, were not 
found in uveal melanomas. 12 13 Hypermethylation of 
RASSF1, RARB and APC has been identified in 
cutaneous melanoma. 14-16 However, except for 
RASSF1 in one recent study, 10 these epigenetic events 
have not been investigated in uveal melanoma. 
In this study, we investigated methylation profiles 
of several genes commonly involved in cancer 
development (p16, TIMP3, RASSF1, RARB, FHIT, 
h TER T and APC) in a series of 23 uveal melanomas. 
We specifically examined key promoter genes that 
have previously been shown to be methylated in 
cutaneous melanoma and other cancers. As loss of 
one copy of chromosome 3 was found in 50% of 
uveal melanomas and associated with metastatic 
disease, 17 we were particularly interested in the CpG 
island methylation status of genes located on 
chromosome 3, namely RASSF1, RARB and FHIT. 
MATERIALS AND METHODS 
Tissue samples 
Uveal melanoma samples were obtained from 
consecutive patients recruited in the Jules Gonin 
Eye Hospital of Lausanne. Cases in which there had 
been previous irradiation were excluded from the 
study. T wenty-three patients (12 female, 11 male) 
were selected; their mean age was 58.4 years (range 
25-84). Table 1 summarises the histopathological 
data. Nine uveal melanomas had involvement of the 
ciliary body. There were 12 medium and 11 large 
uveal melanomas according to Collaborative Ocular 
Melanoma Study (COMS) criteria. Most tumours 
were mixed (n = 14), and the others were spindle cell 
(n = 5) and epithelioid ce!! (n = 4) types. Vascular 
patterns were assessed as previously described.18 The 
local ethics committee authorised the use of human 
tissues for this study. The study adhered to the 
tenets of the Helsinki Declaration. 
DNA extraction and bisulfite modification 
Samples were retrieved from formalin-fixed paraf-
fin-embedded tissue blacks. After deparaffinisa-
tion, selected areas in tumour tissue sections were 
microdissected, and the DNA extracted as pre-
viously described. 19 DNA was modified with 
sodium bisulfite as previously described. 19 
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Table 1 Uveal melanoma histology 
Base Height Cell 
Case Location (mm) (mm) type Vascular pattern 
ch 8 8 M Back ta back loops 
2 ch 11 10 E Arcs with branching 
3 cb 4 4 M Normal 
4 ch 10 M Normal 
5 cb 10 8 s Back to back loops 
cb 15 11 M Back to back loops 
cb 12 18 M Arcs with branching 
ch 9 8 Back to back loops 
cc 18 Back to back loops 
10 cc 10 8 M Back to back loops 
11 ch 11 12 M Back to back loops 
12 ch 20 8 M Normal 
13 ch 18 10 Arcs with branching 
14 cb 4 M Paral\e\ without cross-linking 
15 cc 16 8,5 s Silent 
16 ch 12 M Arcs with branching 
17 ch 13 12 M Arcs with branching 
18 ch 10 8 s Normal 
19 ch 11 11 s Normal 
20 cc 12 13 M Back to back \oops 
21 ch 9 9 s Arcs with branching 
22 ch 4 M Arcs with branching 
23 ch 10 M Back to back loops 
ch, choroidal; cb, ciliary body; cc, ciliochoroidal; M, mixed ce\\ type; S, spindle cell 
type; E, epithe\ioid cell type. 
Methylation-sensitive single-strand conformation analysis (MS· 
SSCA) 
Nested PCR was performed for the seven selected gene 
promoters with the following amplification profile: 94°C for 
30 s, 45 s at Tm, and 72°C for 75 s.2° For the outer PCR, 2 ~LI 
modified DNA was used in a total volume of 20 µl; the inner 
PCR was performed with 1 µl diluted first-PCR product in a 
total volume of 20 µ1. For the outer and inner PCR, 40 and 20 
cycles, respectively, were performed. Table 2 lists conditions and 
primer sequences. Amplification was confirmed by analysis on a 
2% agarose gel. Single-strand conformation analysis was 
performed as previously described. 19 For each gene promoter, 
the percentage of methylated alleles was semiquantitatively 
estimated by comparing the intensity of the methylated and 
unmethylated bands with an external standard. 
Methylation-sensitive dot-blot assay (MS-DBA) 
All amplified PCR samples were submitted to MS-DBA, as 
previously described.20 21 Briefly, NaOH-denatured nested PCR 
products and positive controls were immobilised in duplicate on 
two NytranN membranes (Schleicher and Schuell, Dassel, 
Germany). The probes were labelled using a DIG oligonucleotide 
3'-End Labeling Kit (Roche, Rotkreuz, Switzerland) following the 
manufacturer's instructions. Specific probes were developed to 
detect the amplified DNA. One probe was designed to hybridise to 
methylated DNA containing two CG dinucleotides, and the other 
one contained two TG dinucleotides in order to recognise the 
unmethylated DNA. Table 3 describes the conditions of the dot-
blot and probe sequences. The results were obtained by 
comparing the intensity of the spots on bath membranes. 
Positive and negative contrais 
SssI methylase (New England Biolabs, Beverly, Massachusetts, 
USA) was used to methylate 15-20 µg normal colon DNA 
obtained from frozen colon mucosa. Full methylation was 
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confirmed by digestion with MspI (Promega, Madison, 
Wisconsin, USA) and HpaII (Amersham Biosciences, High 
Wycombe, Buckinghamshire, UK). SssI-methylated and unmethy-
lated DNA were mixed at different ratios to obtain a methylation 
scale (0%, 50% and 100% of methylation), which was used as 
positive contrai. For each ratio, 2 µg DNA was modified with 
sodium bisulfite and amplified by nested PCR as described above. 
RESULTS 
Uveal melanoma samples from 23 patients were analysed for 
the methylation status of seven CpG island promoter genes, 
including p16, TIMP3, RASSF1, RARB, FHIT, hTERT and APC. 
Methylation patterns of the different promoter genes were 
determined by MS-SSCA and MS-DBA. Different patterns of 
methylation were found by MS-SSCA: no methylation, full 
hypermethylation, or a mixture of unmethylated and fully 
hypermethylated alleles in varying ratios (fig 1A). The results 
obtained by MS-SSCA were confirmed by MS-DBA (fig 1B). 
Figure 2 gives detailed results for the DNA methylation analysis 
of the seven genes in uveal melanoma samples. 
Of the uveal melanomas evaluated, 39% (9/23) did not 
contain a significant level of promoter methylation for any of 
the genes studied. Of the 14 cases with at least one methylated 
promoter, only five were methylated for two of the seven 
analysed gene promoters. Only hTERT showed a relatively high 
frequency of promoter methylation (52%; 12/23 cases). A low 
frequency of methylation was observed for RASSF1 (13%), 
RARB (13%), TIMP3 (9%) and p16 (4%). No methylation was 
found for APC and FHIT. 
No correlation was established between promoter methyla-
tion status and either the histopathological characteristics of the 
tumours or the age of the patients. 
DISCUSSION 
Most molecular genetic studies performed on uveal melanoma have 
focused on mutation or allelic loss of tumour suppressor genes 
leading to a loss of gene expression or function. DNA methylation 
resulting in epigenetic silencing of tumour suppressor genes is an 
alternative mechahism for loss of tumour suppressor gene function. 
Patterns with selective methylation of specific tumour suppressor 
gene promoters have been described in a wide range of tumours, 
creating a unique methylation profile characteristic of a particular 
tumour type.4 22 We determined in 23 uveal melanomas the 
promoter methylation profile of seven genes commonly involved 
in tumour development. In our series, hTERT promoter methyla-
tion was found with relatively high frequency (52%). Promoter 
methylation of p16, TIMP3, RASSF1, RARB, FHIT and APC was a 
rare event. For none of these genes did promo ter methylation exceed 
15% of tumour samples, and, for some genes (FHIT and APC), no 
methylation was found at al!. Furthermore, promoter methylation 
was absent in 39% (9/23) of cases. 
Three gene promoters often methylated in cutaneous mela-
noma (APC, RARB and RASF1) were found to be either not or 
rarely methylated in uveal melanoma. The APC gene promoter 
has been found to be methylated in 60% of primary cutaneous 
melanomas and 90% of metastases, 16 but promoter methylation 
of this gene was not identified in any of our series of uveal 
melanomas. Methylation of RARB has been observed in 70% of 
cutaneous melanoma, 15 whereas this epigenetic alteration seems 
to be rare in uveal melanoma (13%). RASSF1 was methylated in 
only 13% of our uveal melanoma compared with 41--49% of 
cutaneous melanomas. 14 15 In a recent study, RASSF1 promoter 
methylation was identified in 50% of primary uveal melanoma, 
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Table 2 
Gene 
p16 
TIMP3 
RASSF1 
RARB 
FHIT 
hTERT 
APC 
Amplicon location, number of CpG sites, primer sequences and PCR conditions 
Amplicon location 
relative to 
GenBank transcription CpG 
accession No start site sites 
AF0022809 -46 ta +126 
10 
AF001361 -189 ta -36 
11 
AC002481 -2 ta +167 
14 
X56849 -306 ta -150 
7 
AF399855iNM _ 002012 -126 ta +42 
11 
AF128893 -387 ta -219 
20 
U02509 -210 ta -52 
13 
PCR conditions 
Tm Mg Cl, 
PCR Primer sequences (5' -3') ('C) (mM) DMSO 
Outer GGGGGAGATTTAATTTGGCAAC 54 1.5 5% 
CCCTCCTCTTTCTT 
lnner GATTTTAGGGGTGTTATATTCAA 54 1.5 
CCCCTCCTCTTTCTT 
Outer GTATTATTTTTTATAAGGATTTG 50 2.0 
CCTACCTACTACCCTCTCTAC 
lnner GGTTTAGI 11111111 IGGAGCC 50 2.0 
TACCTACTACCCTCTCTAC 
Outer CCCCACAATCCCTACACCCAAA 55 1.5 
TGTTTTGGTAGTTTAATGAGTTT 
AGGTTTTTT 
lnner ACTCTCCTCAACTCCTTCCGTTT 54 1.5 
TGGTAGTTTAATGAGTTTAGGTT 
TTTT 
Outer GTAAAGGGAGAGAAGTTGGTGT 55 1.5 5% 
CAACTCCCAAAATTCTCACAA 
lnner AAGGGAGAGAAGTTGGTGTTTA 50 1.5 5% 
AAACAAACAACCAAAAAAACA 
AA 
Outer GTTTTTGAATTAGGGTTATTGTT 53 2.0 
CCTAAAAATATACCCACTAAAT 
A 
lnner GTTATTATGGTTTTTAATTGGTT 50 2.0 
CAAAAAACAAAAAATCCTATAA 
c 
Outer GGGTTATTTTATAGTTTAGGTAA 53 2.0 5% 
TCCCCAATCCCT 
lnner GGGTTATTTTATAGTTTAGGTAA 48 1.5 5% 
TCCACTAAAAACCC 
Outer GGGGTTAGGGTTAGGTAGGAAC 53 1.5 5% 
TACACCAATACAACCACATA 
lnner GGGTTAGGGTTAGGTAGGTTGT 53 1.5 5% 
CCCACACCCAACCAATC 
Table 3 Oligoprobe sequences and conditions for methylation-sensitive dot-blot assay 
Tm Hyb Tm washes 
Gene CG-probe sequences (5'-3') TG-probe sequences (5'-3') (oC) (oC) 
p16 TCGGAGGGGGTTTTTTCGTT GTTGGAGGGGGTTTTTTTGTT 50 53 
TIMP3 GTCGATGAGGTAATGCGGTT GGTTGATGAGGTAATGTGGTT 50 52 
RASSFl CAAAACCAACGAAACACGAAC CAAAACCAACAAAACACAAACC 50 53 
RARB GGAAAGAAAACGTCGGTTTGT GGAAAGAAAATGTTGGTTTGTG 50 53 
hTERT TAGTTGCGTTGTCGGGGTTA GTAGTTGTGTTGTTGGGGTTA 50 53 
FHIT GGTTTCGTTTTTATCGTGGG GGGTTTTGTTTTTATTGTGGG 48 52.5 
APC GATGCGGATTAGGGCGTTTT GGATGTGGATTAGGGTGTTTT 50 53 
and a correlation was found between RASSF1 promoter 
methylation status and the development of meta-
stasis.10 As the same promoter region was evaluated in this study 
and ours, the discrepancy in the results may be explained by the 
selection of tumours of larger size and at a later stage of 
development in the Dutch study. 
Methylation of the hTERT promoter was identified in 52% of 
the uveal melanomas. The first studies of the methylation status 
of the hTERT CpG island had led to a paradox. In normal somatic 
cells, this CpG island was unmethylated while the gene was 
transcriptionally silent. However, in most cancer cells, this region 
was hypermethylated, whereas telomerase activities and hTERT 
mRNA were unambiguously detected. 2326 These observations 
contrast with the general association between promoter methyla-
tion and gene silencing.27 We recently solved this paradox. hTERT 
methylation does indeed prevent binding of negatively acting 
transcription factors, such as CTCF inhibitor,28 and partial 
hypomethylation of the short region of the hTERT promoter 
can result in some level of transcriptional activity.'9 No previous 
studies have evaluated hTERT methylation in uveal melanoma, 
but moderate telomerase activity has been reported in a series of 14 
tumours.30 As telomerase activity and mRNA expression correlate 
with the level of its promoter methylation,25 our data are in 
agreement with this report. However, we were notable to identify 
a correlation between hTERT promoter methylation status and 
tumour morphological characteristics (ce!! type, tumour size, 
tumour localisation, vascular pattern and pigmentation). Likewise, 
Heine et a/30 showed no correlation between telomerase activity 
and morphology or the growth fraction of the tumour. 
Methylation scale 14 
A 
___. 
B 
Unmethyl. 
CpGs 
Methyl. 
alleles (%) 
Methyl. CpGs 
Unmethyl. CpGs 
Methyl. 
alleles (%) 
0 50 100 
Methylation scale 
"' " 
.. .. 
0 50 100 
100 0 
13 
.. 
.. 
100 
14 
0 
In previous studies performed in uveal melanoma, much 
attention has been paid to cell cycle proteins such as p16. Various 
levels of p16 expression have been identified by immunohisto-
chemistry, ranging from complete preservation of expression to loss 
of expression in 15-66% of cases.6 31 32 Loss of heterozygosity of 
9p21 has been reported in 24-32% of cases.6 33 Sequence analysis 
failed to reveal any inactivating mutations.5 6 Inactivation of p16 
can also occur through methylation of its promoter. In our study, 
only one case (6%) showed methylation of the p16 promoter. This 
result corroborates previous studies on primary uveal tumours.6 7 
However, one group found a methylation rate of 32% in primary 
uveal melanomas and 50% in ce!! lines derived from them. 8 The 
discrepancy between these data may be related to the sensitivity of 
the different techniques used for methylation analysis. The p16 
promoter has often been found to be methylated in studies using 
methylation-specific PCR. This technique is the most widely used 
because of its high sensitivity and ease of execution; however, it can 
generate false-positive results through PCR overamplification. In 
contrast, p16 methylation has rarely been detected when MS-SSCA 
or sequencing has been used. Furthermore, analysis of promoter 
methylation in cell lines does not necessarily represent promoter 
methylation status in primary tumour specimens:" 
As monosomy of chromosome 3, an event identified in over 50% 
of uveal melanoma, correlates with the development of metastatic 
disease,17 much attention has been paid to the involvement of 
possible candidate genes located on chromosome 3 in the 
progression of the disease. We evaluated in this context the 
promoter methylation status of three genes located on chromo-
some 3, FHIT, RARE and RASSF1. On the basis of our data, CpG 
15 16 17 18 19 20 
Methyl. 
CpGs 
___, 
0 0 100 0 30 100 
15 16 17 18 19 20 
0 <!> ~ 
"' 
.. 
• " 0 0 0 
.. .. D 0 
0 0 100 0 30 100 
Figure 1 hTERT promoter methylation by methylation-sensitive single-strand conformation analysis (MS-SSCA) and methylation-sensitive dot-blot 
assay (MS-DBA) in uveal melanomas. (A) hTERT promoter methylation by MS-SSCA. Three cases (13, 17 and 20) show full methylation, and another 
?n~ (19) methylation of about 30% of the alleles. Enzymatically methylated DNA from placenta was used as control for the methylation scale. Bars 
lnd1cate the methylated or unmethylated bands. Methylation level (%): 0, no methylation; 50, 50% of methylated alleles; 100, 100% of methylated 
alleles. (B) hTERT promoter methylation by MS-DBA. Dots hybridised with an oligoprobe specific for either the methylated DNA (Methyl. CpGs) or the 
u~rnethyl~ted DNA (Unmethyl. CpGs). The percentage of methylated alleles is indicated under each sample. ln cases 13, 17, 19 and 20, dots are 
0 served in the upper layer as a result of hybridisation with an oligoprobe specific for methylated DNA. 
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Figure 2 (A) Methylation analysis of pl 6, TIMP3, RASSFl, RARB, 
FHIT, hTERT and APC promoters in 23 uveal melanomas. The numbers 
identify the individual cases. The methylation analysis was performed 
using methylation-sensitive single-strand conformation analysis (MS-
SSCA) and methylation-sensitive dot-blot assay (MS-DBA). (B) 
Percentage of methylated samples for each gene. 
island methylation does not appear to be a common mechanism 
involved in the silencing of these genes in uveal melanoma. 
In conclusion, our study indicates that epigenetic alterations 
of the hTERT gene is a significant event in uveal melanoma. 
Promoter methylation of p16, TIMPS, RASSF1, RARE, FHIT 
and APC is rare in primary uveal melanoma. Our findings do 
not, however, exclude silencing of these genes by promoter 
methylation during later tumour progression. They also show 
that different epigenetic events occur in the development of 
cutaneous and uveal melanoma. 
Competing interests: None. 
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